Technical Analysis for CGEM - Cullinan Management, Inc.

Grade Last Price % Change Price Change
F 38.18 0.93% 0.35
CGEM closed up 0.93 percent on Thursday, January 21, 2021, on 46 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A N/A
Historical CGEM trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
NR7 Range Contraction 0.00%
New 52 Week Closing High Bullish 0.93%
Spinning Top Other 12.69%
Bearish Engulfing Bearish 8.84%
New 52 Week Closing High Bullish 1.81%
Up 3 Days in a Row Strength 1.81%
New 52 Week Closing High Bullish 7.91%
Multiple of Ten Bullish Other 7.91%
Gapped Up Strength 7.91%
Older End-of-Day Signals for CGEM ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above Previous Day's High about 8 hours ago
60 Minute Opening Range Breakout about 9 hours ago
Reversed from Up about 14 hours ago
Gap Up Closed about 14 hours ago
Gapped Up (Partial) about 14 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Cullinan Management, Inc. Description

Cullinan Oncology, LLC, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Its lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. The company's preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell acute lymphoblastic leukemia; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. It has a collaboration agreement with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, LLC was founded in 2016 and is headquartered in Cambridge, Massachusetts.


Sector: Other
Industry: Other
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Immunology Solid Tumors Immune System Antibodies Oncology Monoclonal Antibody Cancer Immunotherapy Acute Myeloid Leukemia Non Small Cell Lung Cancer Tumors Cell Therapy Therapies For Cancer Treatment Of Acute Myeloid Leukemia Oncology Therapies B Cell Acute Lymphoblastic Leukemia Preclinical Products

Is CGEM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 43.0
52 Week Low 27.01
Average Volume 327,670
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 0.00
10-Day Moving Average 0.00
Average True Range 0.00
ADX 0.0
+DI 0.00
-DI 0.00
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.00
Lower Bollinger Band 0.00
Percent B (%b) 0.0
BandWidth 0.00
MACD Line 0.00
MACD Signal Line 0.00
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 41.53
Resistance 3 (R3) 41.15 39.67 40.97
Resistance 2 (R2) 39.67 38.81 39.85 40.78
Resistance 1 (R1) 38.92 38.29 39.30 39.30 40.60
Pivot Point 37.44 37.44 37.62 37.62 37.44
Support 1 (S1) 36.69 36.58 37.07 37.07 35.76
Support 2 (S2) 35.21 36.06 35.39 35.58
Support 3 (S3) 34.46 35.21 35.39
Support 4 (S4) 34.84